SLC5A2 and chronic kidney disease: In contrast, in the CREDENCE trial that involved the use of an SGLT2 inhibitor in a high‐risk CKD population (eGFR 56 mL/min1.73 m2 and UACR 927 mg/g), progression to chronic kidney replacement was significantly reduced in 76/2202 (3.5%) versus 100/2199 (4.6%) trial participants treated with canagliflozin versus placebo, respectively (HR: 0.74, 95% CI: 0.55–1.00).35